See more : Tulive Developers Limited (TULIVE.BO) Income Statement Analysis – Financial Results
Complete financial analysis of CalciMedica, Inc. (CALC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CalciMedica, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Nippon Coke & Engineering Company, Limited (3315.T) Income Statement Analysis – Financial Results
- Boltek Holdings Limited (8601.HK) Income Statement Analysis – Financial Results
- Mountain Crest Acquisition Corp. III (MCAEU) Income Statement Analysis – Financial Results
- Public Storage (PSA-PO) Income Statement Analysis – Financial Results
- Alternative Energy Development Corp. (ADEC) Income Statement Analysis – Financial Results
CalciMedica, Inc. (CALC)
About CalciMedica, Inc.
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 58.00K | 52.00K | 519.00K | 395.00K | 303.00K | 175.00K |
| Gross Profit | -58.00K | -52.00K | -519.00K | -395.00K | -303.00K | -175.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 12.36M | 14.11M | 18.90M | 20.96M | 30.58M | 22.97M |
| General & Administrative | 0.00 | 19.10M | 17.04M | 8.87M | 6.92M | 5.60M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.46M | 19.10M | 17.04M | 8.87M | 6.92M | 5.60M |
| Other Expenses | 0.00 | 2.96M | 0.00 | 2.16M | 72.00K | 0.00 |
| Operating Expenses | 21.82M | 33.22M | 35.95M | 29.83M | 37.50M | 28.57M |
| Cost & Expenses | 21.88M | 33.22M | 35.95M | 29.83M | 37.50M | 28.57M |
| Interest Income | 0.00 | 575.00K | 126.00K | 143.00K | 393.00K | 192.00K |
| Interest Expense | 0.00 | 0.00 | 126.00K | 143.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 58.00K | 52.00K | 519.00K | 395.00K | 303.00K | 175.00K |
| EBITDA | -34.19M | -7.64M | -35.30M | -27.14M | -36.73M | -28.20M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -21.88M | -36.18M | -35.95M | -29.83M | -37.50M | -28.57M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -12.48M | 28.36M | 126.00K | 2.30M | 465.00K | 192.00K |
| Income Before Tax | -34.36M | -35.61M | -35.82M | -27.53M | -37.04M | -28.38M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -109.90K | 2.39M | -2.00M | -538.00K | -393.00K | 13.86K |
| Net Income | -34.36M | -35.61M | -35.82M | -27.53M | -37.04M | -28.38M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -7.65 | -23.20 | -23.66 | -58.24 | -35.85 | -33.10 |
| EPS Diluted | -7.65 | -23.20 | -23.66 | -58.24 | -35.85 | -33.10 |
| Weighted Avg Shares Out | 4.49M | 1.53M | 1.51M | 472.75K | 1.03M | 857.28K |
| Weighted Avg Shares Out (Dil) | 4.49M | 1.53M | 1.51M | 472.75K | 1.03M | 857.28K |
CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis
Full target enrollment of 216 patients achieved Topline data from CARPO expected in 2Q 2024 LA JOLLA, Calif., April 24, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel...
CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates
Enrollment in CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP), on track with topline data expected in 2Q 2024 Auxora granted Investigational New Drug clearance by the FDA for Phase 2 trial in severe acute kidney injury (AKI);...
CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference
Therapeutic treatment with Auxora shown to hasten the recovery of kidney function and improve survival in a rat model of acute kidney injury (AKI) Preclinical results are consistent with clinical observations made with Auxora, supporting the KOURAGE trial in patients...
CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference
Preclinical data show that therapeutic treatment with Auxora in a rat model of AKI improves kidney function as measured by glomerular filtration rate LA JOLLA, Calif. , Feb. 28, 2024 /PRNewswire/ -- CalciMedica Inc. (CalciMedica or the Company) (Nasdaq: CALC),...
CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury
Phase 2 trial, expected to begin in 1H 2024, aims to address the unmet medical need of patients suffering from stage 2 or 3 acute kidney injury with associated acute hypoxemic respiratory failure, a condition associated with a high mortality...
CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
LA JOLLA, Calif. , Feb. 7, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that...
Huge Insider Buys From Warren Buffett, Jack Ma, Carlos Slim and More
Overall, the number of notable insider purchases may have dwindled with the earnings-reporting season in full swing, but there were still some huge, headline-making buys in the past week or so.
CalciMedica Announces Private Placement of up to Approximately $55 Million
$20.4 million in upfront financing with the potential to receive up to an additional approximately $34.2 million for an aggregate of up to approximately $55 million Upfront net proceeds to provide funds to expand Auxora™ clinical development to include planned Phase...
CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates
Continued expansion of Phase 1/2 CRSPA study of Auxora™ in asparaginase-induced pancreatic toxicity (AIPT); data from initial cohort to be presented at 65th Annual American Society of Hematology (ASH) Meeting & Exposition International expansion of Phase 2b CARPO trial in acute...
CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition
Auxora ™ showed a 53% reduction in days in hospital, a 40% reduction in intensive care unit (ICU) days and eliminated the need for total parenteral nutrition (TPN) LA JOLLA, Calif. , Nov. 2, 2023 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica")...
Source: https://incomestatements.info
Category: Stock Reports